

Company name: OrthoTreat Ltd. **Website:** www.orthotreat.io

CEO name: Sahar Meiron

Category: Biotech/Pharma

Session: Beyond Bones and Screws: Rethinking Orthopedic Repair

- **Executive Summary / Investment Rational:** OrthoTreat is redefining bone regeneration with a first-in-class dual-drug therapy, ModulX®, that orchestrates the body's natural healing process by targeting multiple biological pathways. With millions of fractures annually and current treatments often falling short, a significant unmet need remains. With strong preclinical data and non-dilutive funding secured, OrthoTreat is raising \$2M to reach IND and advance toward clinical entry.
- **Core Technology:** ModulX® is an osteoregulatory therapy designed to actively coordinate the bone healing cascade across multiple biological pathways. Rather than targeting a single mechanism, it simultaneously modulates osteogenesis, inflammation, vascularization, and resorption, enabling faster, more consistent, and higher-quality bone regeneration. This multi-pathway control positions ModulX® as a platform technology across high-need indications where current treatments fall short.
- **Product Profile/Pipeline:** Our lead product, ModulX-T, is in preclinical development for tibial shaft fractures, with a clear path to IND and first-in-human studies. It is an injectable hydrogel for single administration during fixation, enabling sustained release and seamless clinical integration. The ModulX® platform supports expansion across orthopedic indications and metabolic bone disorders, enabling a broad pipeline with strong clinical and commercial potential.
- **Business Strategy:** OrthoTreat's go-to-market strategy focuses on seamless integration of ModulX® into surgical workflows, targeting orthopedic surgeons, trauma centers, hospitals, and clinics. Adoption is driven through strategic partners with strong market access and networks, aligned with demand for solutions combining efficacy and safety. Initial revenues will come from fracture treatment in the US and Europe, with expansion into additional indications driving growth.
- **What's Next?** OrthoTreat is advancing toward IND approval and FIH clinical trials, supported by ongoing GLP toxicology studies and large animal efficacy data. The team is expanding to support R&D and clinical execution, alongside building a KOL network. The company is currently raising a \$2M pre-Series A, with a planned Series A to fund clinical development and regulatory milestones.